Bristol Myers Squibb Company BMY

62.86 1.36 2.21% as of 25 Sep
Market cap
$125.9B
P/E
13.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Bristol Myers Squibb Company (BMY) P/S ratio

As of 25 September 2026, Bristol Myers Squibb Company (BMY) trades at a P/S ratio of 2.6×. Over the past ten years it has ranged from 1.7× (July 2024) to 7.3× (June 2016); the current reading is higher than 24% of that period. That is below the Drug Manufacturers General industry median of 3.3× and below the Healthcare sector median of 3.8×.

P/S ratio, daily

Annual

Period P/S ratio Change
FY2025 2.3× (4.09%)
FY2024 2.4× (2.14%)
FY2023 2.4× (27.26%)
FY2022 3.3× 11.69%
FY2021 3.0× (9.37%)
FY2020 3.3× (21.30%)
FY2019 4.2× 11.26%
FY2018 3.8× (22.50%)
FY2017 4.9× (5.07%)
FY2016 5.1× (26.15%)

Quarterly

Period P/S ratio Change
Jun 2026 2.4× (6.17%)
Mar 2026 2.5× 11.99%
Dec 2025 2.3× 19.09%
Sep 2025 1.9× (3.20%)
42 more quarters

Against its own ten years

Low 1.7× High 7.3×
Ten-year median 3.4×
Current reading's percentile 24

P/S ratio against peers

Company P/S ratio
SNY Sanofi compare 1.7×
GSK GSK PLC Sponsored ADR compare 2.2×
PFE Pfizer Inc. compare 2.6×
BMY Bristol Myers Squibb Company 2.6×
NVO Novo Nordisk A/S compare 3.3×
AZN AstraZeneca PLC compare 4.2×
NVS Novartis AG compare 4.9×
AMGN Amgen Inc. compare 5.9×
GILD Gilead Sciences, Inc. compare 6.2×
Drug Manufacturers General industry median 3.3×
Healthcare sector median 3.8×
Market median 2.0×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on BMY